| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/15/2004 | WO2004058190A2 Methods for treating taxol-induced sensory neuropathy |
| 07/15/2004 | WO2004058188A2 Vaccine compositions and methods |
| 07/15/2004 | WO2004058183A2 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
| 07/15/2004 | WO2004058178A2 Uses of mammalian cytokine; related reagents |
| 07/15/2004 | WO2004058171A2 Antibodies against gpr64 and uses thereof |
| 07/15/2004 | WO2004058167A2 Breast specific protein expressed in cancer and methods of use thereof |
| 07/15/2004 | WO2004058159A2 Branched immunomodulatory compounds and methods of using the same |
| 07/15/2004 | WO2004058157A2 Yeast-based vaccines as immunotherapy |
| 07/15/2004 | WO2004058156A2 High pressure spray-dry of bioactive materials |
| 07/15/2004 | WO2004058142A2 Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses |
| 07/15/2004 | WO2004058050A2 Amplified cancer target genes useful in diagnosis and therapeutic screening |
| 07/15/2004 | WO2004057968A1 Preparation and administration of hybrid cell vaccines for the prevention of cancer |
| 07/15/2004 | WO2004045561A3 Use of ferritin for immunomodulation |
| 07/15/2004 | WO2004044149A3 Method for suppressing immune system response to transplanted tissue or cells |
| 07/15/2004 | WO2004041865A3 Stabilized single domain antibodies |
| 07/15/2004 | WO2004041863A3 Single domain antibodies directed against interferon- gamma and uses therefor |
| 07/15/2004 | WO2004041853A3 Hcv vaccine compositions comprising e1 and ns3 peptides |
| 07/15/2004 | WO2004039329A3 Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| 07/15/2004 | WO2004034956A3 8-plasmid method with mutated ha gene for producing an influenza vaccine |
| 07/15/2004 | WO2004032599A3 Novel immunogenic proteins of leptospira |
| 07/15/2004 | WO2004031224A3 Hbv mutations associated with reduced susceptibility to adefovir |
| 07/15/2004 | WO2004028442A3 Use of excipients to increase dna uptake by swine muscle cells |
| 07/15/2004 | WO2004026260A3 Prophylactic and therapeutic hiv aptamers |
| 07/15/2004 | WO2004024879A3 RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 07/15/2004 | WO2004020609A3 Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection |
| 07/15/2004 | WO2004019977A3 Improved bacterial outer membrane vesicles |
| 07/15/2004 | WO2004019911A3 Buccal, polar or non-polar spray or capsule containing drugs for treating endocrine disorders |
| 07/15/2004 | WO2004003160A3 Use of adhesion molecules as bond stress-enhanced nanoscale binding switches |
| 07/15/2004 | WO2004002535A8 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 07/15/2004 | WO2003100033A3 ANTI-αvβ6 ANTIBODIES |
| 07/15/2004 | WO2003099226A3 Antibody peg positional isomers, compositions comprising same, and use thereof |
| 07/15/2004 | WO2003093422A3 Novel tissue factor targeted antibodies as anticoagulants |
| 07/15/2004 | WO2003070883A3 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
| 07/15/2004 | WO2003068938A3 Human fetal bladder-derived epithelial cells |
| 07/15/2004 | WO2003064612A3 Identification of mutant antigens with enhanced immunogenicity |
| 07/15/2004 | WO2003063893B1 Fgfr agonists |
| 07/15/2004 | WO2003051912A9 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| 07/15/2004 | WO2003047506A3 Peptide agonists of prostate-specific antigen, and uses therefor |
| 07/15/2004 | WO2003044162A3 Genes encoding g-protein coupled receptors and methods of use therefor |
| 07/15/2004 | WO2003015694A3 Agents for enhancing the immune response |
| 07/15/2004 | US20040138415 Helicobacter proteins, nucleic acids and uses thereof |
| 07/15/2004 | US20040138304 Prodrugs of excitatory amino acids |
| 07/15/2004 | US20040138296 Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease |
| 07/15/2004 | US20040138165 Nucleic acids; drug or gene product; stabilization; gene therapy; purification using free radical scavenger |
| 07/15/2004 | US20040138135 immunogens; immunotherapy; antigen presenting cells |
| 07/15/2004 | US20040138126 Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| 07/15/2004 | US20040138112 Vaccines |
| 07/15/2004 | US20040138101 Prophylaxis of bone disorders comprising administering insulin and derivatives, and optionally in combination with peptide growth factors, metabolic antagonist, osteoprotegerins, synovial or antiinflammatory agents, in sustained release form |
| 07/15/2004 | US20040138095 Colloidal suspension of nanoparticles based on an amphiphilic copolymer |
| 07/15/2004 | US20040137935 Modular personal device system |
| 07/15/2004 | US20040137620 Compositions corresponding to a calcium transporter and methods of making and using same |
| 07/15/2004 | US20040137617 Purification of antigen-specific T cells |
| 07/15/2004 | US20040137601 Amino acid sequences for therapeutic and prophylactic use against diseases due to clostridium difficile toxins |
| 07/15/2004 | US20040137599 Leporipox-based vector vaccines |
| 07/15/2004 | US20040137597 Substrates of N-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates |
| 07/15/2004 | US20040137570 Immunoglobulin 2 |
| 07/15/2004 | US20040137557 Remodeling and glycoconjugation of peptides |
| 07/15/2004 | US20040137554 Diagnosis and treatment of bacterial infections |
| 07/15/2004 | US20040137530 for diagnostic assays/genetically engineering drugs and vaccines |
| 07/15/2004 | US20040137516 DNA sequences from staphylococcus aureus bacteriophage 44AHJD that encode anti-microbial polypeptides |
| 07/15/2004 | US20040137514 Use of antibodies against specific mhc-peptide complexes |
| 07/15/2004 | US20040137513 Agonist anti-trk-c monoclonal antibodies |
| 07/15/2004 | US20040137512 Malaria plasmodium antigen polypeptide se36, method of purifyng the same and vaccine and diagnostic with the use of the thus obtained antigen |
| 07/15/2004 | US20040137492 Novel polypeptide |
| 07/15/2004 | US20040137429 Of given nucleotide sequence; Complexed with a toxin moiety; Use in treating human immunodeficiency virus (HIV) |
| 07/15/2004 | US20040137426 Gp41 peptides and methods based thereon for inhibiting HIV fusion to target cells |
| 07/15/2004 | US20040137087 Processes of making North American ginseng fractions, products containing them, and uses as immunomodulators |
| 07/15/2004 | US20040137085 Treatment of HIV infection with humic acid |
| 07/15/2004 | US20040137018 Aspergillus vaccine preparation and methods of making and using thereof |
| 07/15/2004 | US20040137017 amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment of the amino acid sequence of subunit A of an Escherichia coli heat labile toxin (LT-A) or a fragment, where in Ser-63 and Arg-192 are replaced with another amino acid |
| 07/15/2004 | US20040137016 glycosylated or is partially glycosylated ; mutant pre-S in which one or both asparagines of a wild-type pre-S at amino acid position 15 or 123 are substituted by specific amino acids |
| 07/15/2004 | US20040137015 equine influenza virus genome segment confers at least one identifying phenotype of a cold-adapted equine influenza virus on the reassortant virus, and genetically-engineered equine influenza viruses, produced through reverse genetics |
| 07/15/2004 | US20040137014 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 07/15/2004 | US20040137013 Live vaccine and method of manufacture |
| 07/15/2004 | US20040137011 Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance |
| 07/15/2004 | US20040137010 gp120 and a nucleic acid aptamer that binds to gp120 and induces gp120 to undergo a conformational shift whereby an epitope to a membrane bound receptor is exposed that is capable of eliciting a humoral immune response |
| 07/15/2004 | US20040137007 includes polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides |
| 07/15/2004 | US20040137005 Chlamydia protein, sequence and uses thereof |
| 07/15/2004 | US20040137003 Regulated antigen delivery system (rads) |
| 07/15/2004 | US20040137001 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| 07/15/2004 | US20040136999 Melanoma antigens and methods of use |
| 07/15/2004 | US20040136997 Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 07/15/2004 | US20040136995 antibody, or fragment thereof, that specifically binds an ACT-4-h-1 receptor; has different binding specificity than a monoclonal antibody generated by hybridoma HBL106 |
| 07/15/2004 | US20040136993 inducing an immunogenic response against alpha-SN |
| 07/15/2004 | US20040136992 modulating inflammatory and immunoregulatory responses associated with cardiovascular disease with soluble receptor, fusion proteins, and/or antibodies of IL-17, IL-18 antagonist, 4-1BB, CD30 and OX40 |
| 07/15/2004 | US20040136991 Treatment of anemia using TNFalpha inhibitors |
| 07/15/2004 | US20040136990 Treatment of pain using TNFalpha inhibitors |
| 07/15/2004 | US20040136989 Kawasaki's Disease; Behcet's disease; TNF alpha antibody, or an antigen-binding fragment |
| 07/15/2004 | US20040136983 as anti-tumor agent or treating excessive vascular permeability; agonist for treating trauma to vascular network |
| 07/15/2004 | US20040136979 block, retard or reduce connective tissues regeneration; molecules released by catheters, surgical instruments or stents for angioplasty to prevent restenosis; atherosclerosis |
| 07/15/2004 | US20040136972 Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| 07/15/2004 | US20040136963 Simian adenovirus vectors and methods of use |
| 07/15/2004 | US20040136962 Ordered molecular presetation of antigens, method of preparation and use |
| 07/15/2004 | US20040136951 Death domain containing receptor 5 |
| 07/15/2004 | US20040136950 enhancing apoptosis induced by a TNF-family ligand, which involves administering to a cell that expresses the DR4 polypeptide an effective amount of an agonist capable of increasing DR4 mediated signaling |
| 07/15/2004 | US20040136949 Combination therapy using anti-angiogenic agents and tnf alpha |
| 07/15/2004 | US20040136948 Branched immunomodulatory compounds and methods of using the same |
| 07/15/2004 | US20040136908 Anti-cd19 immunotoxins |
| 07/15/2004 | CA2756797A1 Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| 07/15/2004 | CA2511910A1 Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |